We are excited to announce that TCGX joined the Series B financing of Beacon Therapeutics (https://www.beacontx.com/). Beacon is a pioneering gene therapy company advancing best-in-class programs for X-linked retinitis pigmentosa and dry age-related macular degeneration. This investment funds Beacon's registrational Phase 3 clinical trial in XLRP and Cariad Chester, Managing Partner at TGCX, has joined the Board of Directors. We look forward to working with our friends at Forbion and Syncona Limited to rapidly advance these transformative therapies. For more information on Beacon, please see the press release: https://lnkd.in/eZ9mrd6K
TCGX
Biotechnology Research
Extraordinary continues here...TCGX is a science-driven investment firm dedicated to advancing disruptive medicines.
About us
TCGX is a registered investment advisor based in Palo Alto, California. TCGX invests in both private and public opportunities, focusing on innovative pre-IPO and public drug discovery companies. We invest in visionary entrepreneurs leveraging recent scientific breakthroughs to develop transformative medicines.
- Website
-
http://www.tcgcrossover.com
External link for TCGX
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Type
- Partnership
Employees at TCGX
Updates
-
TCGX led the $120M Series B financing this week into Pheon Therapeutics, a London-based biopharma company that are developing three ADC assets for the targeting of hard-to-treat solid tumor cancer cells. Our Managing Partner, Cariad Chester, will join the Board of Directors at Pheon. To learn more about the deal, please read below: https://lnkd.in/edC3iPgX
Pheon Therapeutics | LinkedIn
uk.linkedin.com
-
a special congratulations to the awardees from Tuesday night's Gala at The Plaza in Manhattan to celebrate excellence & leadership in the Pan-Asian business community. This gala was hosted by Ascend which aims to promote and advance Asian & Pacific Islander (API) professionals globally. Dr. Chen Yu, Managing Partner and Founder of TCGX, was celebrated for his tremendous accomplishments and for the leadership & standard of excellence he has set as an Asian-American entrepreneur and biotech investor propelling innovation in life science & drug discovery. https://lnkd.in/gTicTsD7
What an absolutely unforgettable way to kick off heritage month in celebration of our community! 🌟 Our 2024 A-List awards are officially wrapped. From inspiring speeches to making new connections and sharing laughter, every moment was incredible. Huge shoutout to all who joined us last night, and a massive congratulations to our amazing honorees! 🎉 You all exemplify what's possible when we come together and strive for excellence. #AListAwards2024 #AList #Ascend #leadership #theplaza #NYC Hannah Yang (The New York Times), Shamina Singh (Mastercard), Chen Yu (TCGX), Aradhana Sarin (AstraZeneca), Ida Liu (Citi), Rajat Puri (Elevance Health), Susie Nam (Publicis Groupe), Dylan Tyson, CFA (Prudential Financial), Janet L. (Kaiser Permanente), Gunjan Kedia (U.S. Bank), Valerie Wong Fountain, CFA (Morgan Stanley), Rita T. (Bristol Myers Squibb), Ketan Majmudar (Synchrony), Dipti Gulati (Deloitte), Edward J. Lee (Kirkland & Ellis), Jing Wang (Vanguard), Jim Fitterling (Dow), Swamy Kocherlakota (S&P Global), Zeeshan Sheikh (PSEG), Tapaswee Chandele (The Coca-Cola Company)
-
+2
-
TCGX reposted this
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million https://lnkd.in/ePTuMRun
-
TCGX, a later-stage clinical phase biotechnology firm, is delighted to announce the closing of a $1B oversubscribed Fund II as of this morning. The TCGX team are delighted to continue our partnerships across both the private and public biotech company landscape as we continue to fuel the surge of innovation we are seeing across life sciences. We want to thank our limited partners for their support and the phenomenal CEOs we have worked with since we established TCG Crossover back in 2020.
-
We are happy to share news of another M&A outcome for TCGX and our active investment into life-changing therapeutics for weight-loss & obesity as part of our active metabolic theme. Earlier this week, Carmot Therapeutics entered into a definitive merger agreement with Roche: https://lnkd.in/gDRESJkU
Carmot Therapeutics Enters into Definitive Merger Agreement with Roche | Carmot Therapeutics | Drug Discovery and Development
https://carmot.us